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Abstract  
Background  
Sjögren’s syndrome (SS) is an autoimmune inflammatory disease that affects the 
exocrine glands. The absence of early diagnostic markers contributes to delays in its 
diagnosis. Identification of changes in the protein profile of saliva is considered one of 
the promising strategies for the discovery of new biomarkers for SS.  
Objective 
To identify salivary protein biomarkers with potential for use in discriminating between 
different lymphoma risk sub-groups of SS.  
Method 
Parotid and whole mouth saliva samples were collected from SS patients, including 
those in sub-groups at higher risk of developing or with confirmed lymphoma, non-SS 
sicca disease controls and healthy subjects. An initial proteomics analysis by mass 
spectrometry (LCMSMS) identified S100A8/A9 as a biomarker and was followed by 
validation with an enzyme linked immunosorbent assay (ELISA).  
Results  
Significant differences were found in levels of S100A8/A9 in parotid saliva but not 
whole mouth saliva between SS patients compared with healthy and disease control 
subjects (p=0.001 and 0.031respectively).  Sub-groups of SS patients based on 
lymphoma risk showed significant differences in salivary levels of S100A8/A9.  
Conclusion 
The results suggest that salivary levels of S100A8/A9 can aid in differentiating 
between SS, disease control and healthy control subjects, especially the sub-groups 
of SS with lymphoma or at higher risk of lymphoma.   
 
 
 
 
 
3 
 
Introduction 
Sjögren’s syndrome (SS), also known as autoimmune exocrinopathy and autoimmune 
epitheliitis, is a systemic, chronic, inflammatory, autoimmune disease that affects the 
exocrine glands, particularly the salivary and lacrimal glands. The pathogenesis of the 
disease remains uncertain and to date no universally effective therapy is available. 
Clinically, dry mouth (stomatitis sicca or xerostomia), dry eyes (keratoconjunctivitis 
sicca (KCS) or xerophthalmia) and fatigue with /without inflammatory arthritis are 
among the most common manifestations1.  
The absence of early diagnostic markers contributes to delays in the diagnosis of SS 
and there is a well-recognized need for the identification and validation of biomarkers 
to be used in diagnosis, prognostic assessments, as a research tool and probably to 
identify novel targets for therapeutic intervention in SS.  The evaluation of the 
composition of saliva, which can be non-invasively collected, could provide biomarkers 
for SS2. Changes in salivary proteins can reflect the pathogenesis of SS, since salivary 
glands are the major source of salivary proteins and a major site of autoimmune 
destruction; saliva is therefore an appropriate body fluid for biomarkers of SS3. There 
is a 1000-fold increased risk of lymphoma development in parotid glands from SS 
patients4. Parotid saliva is therefore a valuable substrate that might be used to 
differentiate between different sub-groups of SS patients; those at higher risk of 
developing mucosa associated lymphoid tissue lymphoma (MALT-L) and those who 
have developed MALT-L.   
Since the first proteomic study on parotid saliva of SS patients in 1999 by Beeley and 
Khoo5, salivary proteomics has remained one of the most promising approaches to 
human disease biomarker identification with the advantage of being non-invasively 
sampled. Several proteomic studies have shown differential protein expression in the 
saliva of SS patients and healthy control subjects6,7 and some studies have validated 
candidate markers8.  A few studies have performed proteomics analysis of saliva 
samples from lymphoma patients9,10.   
 
In the present study, it was hypothesized that SS related proteins exist in human saliva 
and could be used to discriminate SS patients from control subjects. Furthermore, 
identified salivary biomarkers could be useful in identifying a sub-group of SS who may 
be at higher risk of developing or who already have developed lymphoma.  In order to 
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address the study aims a proteomic analysis of parotid saliva samples from healthy 
subjects, SS patients and SS patients at higher risk of developing lymphoma was 
undertaken and potential protein biomarkers identified. A candidate biomarker 
(S100A8/A9 heterodimer) was selected and validated by immunoassay of larger 
groups of samples including disease (dry mouth) control subjects and SS patients who 
have developed lymphoma. The marker was further tested on whole mouth saliva 
(WMS) and differences between both types of saliva were compared. 
 
Materials and methods 
Study group 
The protocol for this study was reviewed and approved by the National Research 
Ethics Service (NRES) Committee (11/LO/1121). Patients with symptomatic dry mouth 
attending Guy’s and St. Thomas’s Hospital Oral Medicine department (GSTT NHS 
Foundation Trust) were included. Recruited patients were originally classified using  
the American-European Consensus Group (AECG) criteria11.  Later patients were re- 
classified according to the ACR criteria12  and some were included as SS patients in 
the present study (total n=51; mean age ±SEM, 52.3±1.6). Sjögren’s syndrome 
patients were further sub-grouped into three groups:  
a) SS-M patients who had been diagnosed with a  MALT lymphoma (M), which had 
been confirmed by histopathological assessment of biopsies of parotid glands, minor 
salivary glands or submandibular gland, (n=14; mean age ±SEM, 53.7± 2.6).  
b) SS at risk group: SS patients classified as high risk of developing MALT-L (SS-HR, 
n=18; mean age ±SEM, 51.9± 3), on the basis of three or more markers of severe SS 
(parotid enlargement, cryoglobulinaemic vasculitis, hypocomplementaemia, 
cryoglobulinaemia, high focus score, germinal centre in their biopsy and previous 
lymphoma), and  SS-LR classified as low risk patients with less than three markers 
but could be  associated with other generalised inflammatory factors -including raised 
β2 microglobulin levels, lymphopenia and hypergammaglobulinaemia13. SS-LR (n=19; 
mean age ±SEM, 51.5 ±2.7).  c) SS sub-group (n=19; mean age ±SEM, 51.5 ±2.7) 
who were not considered at risk of developing MALT nor developed it. 
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Nineteen of the 51 SS patients were determined to have another autoimmune disease 
(e.g. rheumatoid arthritis, systemic lupus erythematosus and scleroderma, see 
supplementary material Table S1. Dry mouth patients  complaining of  xerostomia  with 
hyposalivation, with a negative serology test for SS while having non- specific 
sialadenitis on their biopsy results and confirmed nodal osteoarthritis were diagnosed 
as SNOX 14 and were included as a disease control patient group (n=14; mean age 
±SEM, 62.7±2.6). A further control group was formed from healthy subjects not taking 
medication, with no complaints of oral or ocular dryness and no oral mucosal diseases 
(n=18; mean age ±SEM, 50.7±2.6).  
 
Collection of parotid and whole mouth salivas 
Unstimulated whole mouth saliva (WMS) samples were collected over ten minutes 
followed by stimulated parotid saliva samples over 10 minutes. All saliva samples were 
immediately placed on ice and transferred to the laboratory where they were 
processed by centrifugation at 9500 g for 10 minutes (WMS) and 5 minutes (parotid 
saliva). Samples were split into a number of aliquots and stored at -80 °C until required. 
None of the aliquots were used more than once per assay. A minimum of 1hr fasting 
preceded all sample collections, which were undertaken between 09.00-12.00hr. 
Detailed protocols of saliva collection, flow rates and total protein concentrations 
(Bicinchoninic Acid assay; Thermo Scientific, Rockford, Illinois, USA) are described in 
supplementary material 2, 3 &4. 
Proteomic analysis of parotid saliva 
A pilot proteomics analysis was performed on parotid salivas from SS patients in order 
to identify potential biomarkers associated with parotid gland involvement and an 
increased risk of developing MALT-L. Parotid salivas from healthy subjects (n=2), SS 
patients (n=2) and SS patients at risk of developing MALT-L (n=2) were subjected to 
a proteomics analysis using LDS gel electrophoresis followed by trypsin digestion, 
peptide separation and mass spectrometry (LCMSMS) (see Supplementary material). 
The final selection of upregulated proteins was based on a ≥2 fold increase in both 
diseased samples (SS and SS at risk of MALT-L) when compared with healthy controls 
then in SS at risk of MALT-L when compared with SS (Supplementary material 5). 
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Enzyme linked immunosorbent assay (ELISA) 
Commercially available pre-coated plates (Quantikine ELISA Kit, R&D Systems, 
Minneapolis, MN), (cat. no. DS8900) for S100A8/S100A9 heterodimer were used for 
both parotid saliva and WMS. The samples were thawed and diluted at an optimised 
dilution factor of 1/500 for WMS and 1/200 for parotid saliva. Standards and samples 
were loaded in duplicate. Incubations were done at room temperature on a horizontal 
orbital microplate shaker. All materials were supplied with the kit and the 
manufacturer’s instructions were followed. 
Data analysis 
All results were exported to Windows® Excel 2007 spread sheets, statistical analyses 
for ELISA data were carried out using SPSS (IBM Corporation) and GraphPad Prism® 
6 (GraphPad Software Inc., California, USA) was used for the graphical presentation. 
The Kruskal-Wallis test followed by Dunn’s post-hoc test, was used to determine the 
differences between groups when comparing the mean amount of S100A8/S100A9 
present in the salivary samples of the 5 different groups of participants.  A study with 
80% power and an effect size of 0.42 was determined to require a total sample of 75 
(15 per group) for comparison of the protein levels at a 5% level of significance using 
a two-tailed test (G*power version 3.1.5 software). The median and quartiles were 
used as estimates of central tendency and dispersion. The significance level was set 
to p<0.05. 
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Results 
Salivary flow rates and total protein concentrations  
Parotid saliva samples were collected from 83 (100%) subjects while WMS was 
collected from 56/83 (68%). Insufficient samples were mostly from the patient groups; 
SS-LR 11/19 (57%), SS-HR 8/18 (44%), SS-M 7/14 (50%) and SNOX 12/14 (85%). 
WMS samples were collected from all 18 of the healthy control group.  There were 
statistically significant reductions in the SS group compared to control group as well 
as for some of its sub-groups regarding flow rate and total protein concentration in 
WMS but parotid saliva only showed a difference in flow rate between the healthy 
control and SS (M) groups (Figure 1).  
 
Proteomics analysis of parotid saliva 
Four upregulated proteins; Actin cytoplasmic 2, Ig γ-1chain C region, S100-A8, and 
S100-A9 were finally selected as candidate biomarkers (Supplementary material Fig. 
S1). S100-A9 was not present in the healthy control subject sample in the first run 
while present in both disease samples. When comparing both disease samples of SS 
at MALT-L risk and SS only patients, both S100-A8 and S100-A9 were increased by 
two fold in both runs (Figure 2). 
 
Salivary S100A8/A9 levels  
Parotid saliva  
The median concentration (Q1-Q3) of S100A8/A9 in parotid saliva from overall SS 
patients was 743.1 (91- 3526) ng/mL, which was significantly higher than 
concentrations in healthy (31.9; 0- 273.2 ng/mL) and disease control (208.9; 0- 265.3 
ng/mL) subjects (Figure 3A).  The median concentration of S100A8/A9 in the whole 
group of SS patients was 506 (84.6- 1031) ng/mL.  The mean concentrations were 
statistically significantly higher in SS-HR patients (666.8; 131.2- 5642 ng/mL) and SS-
M patients (937.4; 90- 4566 ng/mL) compared with healthy controls (Figure 3B). The 
values in the SS-LR group were not significantly raised. 
Two patients in the SS-HR group presented with unilateral parotid swelling and the 
S100A8/A9 levels were compared between salivas from the right and left parotid 
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glands of the same patient (n=2). Higher levels were detected in salivas from the 
swollen side for both patients (Supplementary material, Table S2). The higher 
S100A8/A9 levels were confirmed when the samples were assayed a second time.  
Whole mouth saliva  
The median (Q1-Q3) S100A8/A9 concentration was twenty fold higher in WMS from 
the overall SS group (16628; 3165 - 20184 ng/mL) compared with parotid saliva.  
There was no statistically significant difference with concentrations of S100A8/A9 in 
WMS from the healthy (8457; 687.3- 17154 ng/mL) and disease control (3857; 2418- 
8697 ng/mL) groups (Figure 3C).  However, SS sub-groups did show significantly 
higher levels, also the median concentration in SS-M patients (22545; 16032- 28096 
ng/mL) was higher than the healthy control group (p=0.046), SNOX group (p=0.009) 
and the SS sub-group (5244; 1550- 17225 ng/mL) (p=0.049; Figure 3D). 
In both parotid and WMS, there was no statistically significant (Mann–Whitney U test) 
differences detected between patients with or without another autoimmune disease 
(AID) (Figure 3A & C), although a few subjects with high concentrations had another 
AID. No statistically significant (Mann–Whitney U test) differences were detected 
between patients at high and low risk of developing lymphoma (Figure 3B & D).  
 
Sensitivity and reproducibility of S100A8/ A9 immunoassay  
The accuracy of the ELISA was tested for whole mouth saliva (n=1) and parotid saliva 
(n=2) by spiking samples with a known concentration of S100A8/A9. The mean 
recovery (accuracy) of the three samples was 107.7% and ranged between 80.5 and 
142.9%. The linearity was reported by the manufacturer (spiked whole mouth saliva) 
(n=4) with a range of 92-115% for dilutions 1:2, 1:4, 1:8 and 1:16 (Supplementary 
material, Figure S2). 
The reproducibility (intra-assay precision) of ELISA was determined as the mean 
coefficient of variation (CV) of five replicates of three samples (positive parotid saliva) 
in one assay (Table 1.) The inter-assay precision was 8.2 % using two samples tested 
on six separate plates, these were comparable to the values reported by the 
manufacturer (2.7- 4.5% for the intra- assay CV and 3.2- 5.8% for the inter- assay CV). 
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Associations of S100A8/A9 levels in whole mouth and parotid saliva and their 
relation to their flow rates 
There was a weak positive correlation between the salivary levels of S100A8/A9 in 
matched parotid and WMS from the same patients (n=56; Spearman r=0.268, 
p=0.046; Figure 4.). A stronger correlation was found when only SS sub-groups were 
analysed (n=26) (Spearman r=0.496, p=0.01). A significant correlation was not found 
in samples from healthy control subjects (n=18; Spearman r=0.106, p=0.67). There 
was a negative (inverse) correlation between the parotid salivary levels of S100A8/A9 
and parotid flow rates (Spearman r=0.256, p=0.02) but not with whole mouth saliva 
flow rates (Spearman r=0.138, p=0.309). 
 
Discussion 
Results from the pilot proteomics analysis of parotid saliva suggested that levels of 
S100A8 (Calgranulin A) and S100A9 (Calgranulin B) not only discriminate between 
SS and healthy controls, but also between patients with SS MALT-L and those without 
lymphoma. This suggests the possibility that S100A8/A9 might act as a biomarker for 
the development of lymphoma. S100-A8 and S100-A9 are myeloid-related pro-
inflammatory members of the Alarmin family and are predominantly found as a 
S100A8/A9 24 kD heterodimer that plays a prominent role in the regulation of chronic 
and acute inflammation, inducing leukocyte chemotaxis and adhesion. S100A8/A9 
has been reported as being up-regulated in different cancers 15,16 and increased 
S100A9 protein expression is linked with autoimmune and inflammatory diseases such 
as rheumatoid arthritis, systemic sclerosis and systemic lupus erythematosus17.   
Results from the subsequent immunoassay of larger numbers of parotid salivas 
supported and extended the proteomics findings, showing increased expression of 
S100A8/A9 in parotid saliva of SS groups compared with both healthy controls and 
non-SS dry mouth (SNOX) disease controls.  A higher proportion of parotid salivas 
from the MALT-L associated SS groups showed concentrations above 2000 ng/mL 
but the median values were not statistically significantly different from the SS group 
without MALT-L association.  Interestingly it was noted that when comparing left and 
right glands of two patients at risk of developing MALT-L, the swollen glands showed 
increased level of S100A8/A9 compared to the contralateral unswollen gland, which 
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suggested that increased S100A8/A9 expression reflects a localised inflammatory 
activity. Levels of S100A8/A9 in WMS were higher than parotid saliva but did not show 
statistically significant increases in SS compared with the healthy and disease 
controls.  A possible explanation is that despite being strict in selecting age-matched 
healthy controls who were not on any xerostogenic medication, it might be that other 
influences on oral health status (e.g. caries) affected S100A8/A9 levels in whole mouth 
saliva.  Other sources, in particular gingival crevicular fluid, contribute to S100A8/A9 
in WMS and it should be noted that almost a third of the SS subjects were not able to 
produce whole mouth saliva. Sub-grouping of SS has revealed significant differences 
in whole mouth S100A8/A9 levels of MALT-L patients when compared to the other 
sub-groups. This may be related to the important link of S100A8/A9 to cancer as an 
amplifier of inflammation associated tumour development, which has been previously 
reported15,16.  Since the total protein concentration of whole mouth saliva tended to 
increase in SS associated with MALT-L compared to other groups a comparison of 
S100A8/A9 levels between the groups was made after adjusting the values to total 
protein (ng/mg) but the higher levels in MALT-L remained significant.   
The results from previous studies 18-23 of salivary S100A8/A9 levels in healthy control 
and SS subjects are summarised in Table 2. Most previously published studies in SS 
have assayed stimulated WMS and the mean values in control subjects are higher 
than the present study, which utilized unstimulated WMS. Readings  comparable to 
those of the present study were obtained by Sweet et al. showing a wide range of 
S100A8/A9 levels in unstimulated WMS (200-18000 ng/mL) but significantly higher 
concentrations in SS patients18, a finding in contrast to the present study. While Cuida 
et al. did not show a significant difference in parotid salivary S100A8/A9 between SS 
and control subjects they did report a positive correlation between parotid salivary 
levels and minor salivary gland focus scores of SS patients23.   In our study, a group 
of non-SS sicca disease control subjects diagnosed with non-specific sialadenitis, 
nodal osteoarthritis & xerostomia (SNOX) was included.   SNOX has been little studied 
since its first description by Kassimos et al., 14 and later by others 24,25 it was therefore 
of interest to follow this disease group further. SNOX is often confused with SS and is 
sometimes incorrectly called pre-SS and shares some symptoms; fatigue, complaints 
and signs of dry mouth and dry eyes; inflammation of the minor salivary glands (non-
specific vs. focal in SS groups). Levels of S100A8/A9 in the SNOX group were not 
significantly elevated in parotid saliva and WMS compared with healthy control 
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subjects, which suggested that the sialadenitis and degree of parotid inflammation in 
SNOX patients is less than in SS patients.  
A potential limitation of the present study is that some patients with MALT-L were 
receiving immunosuppressive therapy. However, a comparison of treated and 
untreated patients did not show a difference in mean S100A8/A9 levels 
(Supplementary material, Figure S3). This might also be due to insufficient power of 
the study to determine an effect of drugs in this heterogeneous group of patients. 
Furthermore, the small sample size of the proteomics analysis should be noted and it 
would be of great significance to conduct the same comparison on a larger group of 
patients to check for the reproducibility of the results. 
This study supports previous reports indicating the value of saliva as a diagnostic tool 
for assessing disease activity and progression in Sjögren’s syndrome. The preliminary 
results of parotid saliva proteomic analyses provided a list of candidate biomarkers of 
SS and SS at risk of lymphoma.  It may be that a combination of S100A8/A9 with 
another parotid salivary molecular or other biomarker, for example parotid 
ultrasonography (Jazzar et al., submitted), could provide a more robust diagnostic tool.  
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Figure legends: 
Figure 1. Whole mouth saliva flow rate (A), its total protein concentration (C) (n=56), 
parotid saliva flow rate (E) and its total protein concentration (G) (n=83) of different 
groups. (A & C) and (E & G) SS groups are combined (B & D) and (F & H) SS sub-
groups.  
CT; healthy controls, SNOX; sialadenitis, nodular osteoarthritis and xerostomia, SS; 
Sjögren’s syndrome, MALT-L; mucosa associated lymphoid tissue lymphoma, at risk; 
at risk of MALT-L.  Data are reported as median ± (IQR) and expressed as mL/min.  
(Kruskal-Wallis test followed by Dunn’s post hoc test). 
 
Figure 2. The most over expressed proteins in SS patients compared to control 
subjects, as determined by proteomics analysis of parotid saliva samples. (A) Three 
proteins in the first run *, (B) Four proteins in the second run. The process of selection 
involved comparison of relative expression levels (fold change ratio) of proteins 
identified by proteomics analysis between control samples and samples from patients 
with SS at risk of developing MALT-L and between control samples and SS samples. 
A secondary comparison of proteins was done after log (log2) transformation of the 
raw ratios. A final comparison between both runs was performed following their 
individual analysis where differences between both disease samples (SS and SS at 
risk) were identified 
SS; Sjögren’s syndrome, MALT-L risk; SS patients at risk of developing mucosa 
associated lymphoid tissue lymphoma. * Protein S100-A9 was not detected in the 
control sample. 
 
Figure 3. Concentration of S100A8/A9 in parotid saliva (A & B) (n=83) and whole 
mouth saliva (C & D) (n=56) from different groups. (A & C) SS groups are combined 
(B & D) SS sub-groups.  
CT; healthy controls, SNOX; sialadenitis, nodular osteoarthritis and xerostomia, SS; 
Sjögren’s syndrome, MALT-L; mucosa associated lymphoid tissue lymphoma, at 
risk; at risk of MALT-L, -/+ with or without, AID; autoimmune disease.  
Data are reported as median ± (IQR) and expressed as ng/mL.  
(Kruskal-Wallis test followed by Dunn’s post hoc test). 
 
  
Figure 4. Spearman rank correlations of S100A8/A9 levels from parotid and whole 
saliva of all subjects (n=56). CT; healthy controls, SNOX; sialadenitis, nodular 
osteoarthritis and xerostomia, SS; Sjögren’s syndrome. 
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 Table 1. Intra-assay precision of S100A8/A9 ELISA assay tested on parotid saliva 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Summary of salivary levels of S100A8/A9 in the published literature  
 
Sample1 Sample2 Sample3 Overall 
mean  
Measurements (n)  5 5 5 - 
Mean (ng/mL)  3550.3 7268.9 2034.4 4284.5 
Standard deviation  124.6 313.9 59.6 166.03 
CV (%)  3.5 4.3 2.9 3.9 
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Study references saliva Mean CT 
levels(ng/mL) 
Mean SS 
levels(ng/mL) 
Significant 
Sweet et al. 200118 sParotid  300 - - 
 uWhole 2000 14000 Yes 
     
Muller at al.199219  sParotid 
  
207 *  -  -  
     
Cuida et al.199320 
 
 
sWhole 
 
 
27100 
 
 
29000 
 
 
No 
 
 
Brun et al.199421 
 
 
sWhole 
 
 
27100 
 
 
23624 
 
 
No 
 
 
Cuida et al. 199522 uParotid  3200 - -  
sWhole  22000 - - 
     
Cuida et al. 199723 sParotid  2700 5500 No  
sWhole   15200 36300 No      
our results sParotid 251.4 1968.8 Yes  
uWhole 9545.2 13401 No 
*median, uWhole; unstimulated whole saliva, sWhole; stimulated whole saliva, sParotid;      
stimulated parotid saliva, uParotid; unstimulated parotid saliva. CT; healthy controls, SS; 
Sjögren’s syndrome. 
 
 
 
 
 
 
 
 
 
 




